Wyeth Pharmaceuticals and Ambrx have announced a new alliance to discover, develop and commercialise protein drug candidates for three undisclosed targets in multiple therapeutic areas.

The alliance will focus on Ambrx’s success in applying its protein medicinal chemistry platform to proteins produced in mammalian cells such as antibodies and antibody-toxin conjugates.

Through the agreement, Ambrx expects to earn near-term payments from an upfront commitment, target loading fees and research funding. In addition, Ambrx will be eligible to receive escalating preclinical, clinical, regulatory and commercial milestone payments as well as tiered royalties on sales of products resulting from the collaboration.

Wyeth Research president Mikael Dolsten said that Wyeth is committed to sustaining and growing capabilities in the field of biologics drug discovery.

“Ambrx has the ability to create and advance precisely engineered biologic drug candidates into clinical trials using its proprietary platform,” Dolsten said.